CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Cancer Network
High ImpactOriginal article

<![CDATA[FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma]]>

NDA FilingmezigdomidePositive
AI Analysis

Summary

The FDA has accepted an NDA for mezigdomide combination therapy in relapsed/refractory multiple myeloma, with a PDUFA decision date assigned for May 13, 2027.

Outcome Details

FDA accepted NDA for mezigdomide regimen

Importance:8/10
Sentiment:
0.70
FDANDA acceptancePDUFAmultiple myelomamezigdomide

Read the original article

Published by Cancer Network on July 13, 2026 2:45 PM

Read Original